10 Best Debt Free Blue Chip Stocks to Invest In

8. Intuitive Surgical, Inc. (NASDAQ:ISRG)

On April 14, 2026, Truist lowered its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $580 from $650 and maintained a Buy rating as part of a broader Q1 preview across MedTech. The firm said it expects first-quarter performance to come in at or above expectations despite what it described as anxious investor sentiment around procedure volumes. Truist added that Intuitive Surgical continues to warrant a premium valuation, supported by sustained procedure growth and a new product cycle that could drive further acceleration in revenue and EPS.

On April 12, 2026, BTIG analyst Ryan Zimmerman lowered the firm’s price target on Intuitive Surgical to $574 from $616 and kept a Buy rating, reflecting model updates tied to the CMS proposed rule for the FY27 inpatient prospective payment system. The proposal includes preliminary guidance on new technology add-on payments, which could influence reimbursement dynamics across the sector.

Last month, the FDA said it is reviewing a safety issue involving certain curved-tip staplers used with Intuitive Surgical’s da Vinci Surgical System. The company issued a notice to customers on March 11, 2026, advising them to identify, stop using, and quarantine affected products, and to notify any downstream users to return impacted units. Intuitive also recommended using alternative options. The issue involves reports of incomplete staple line formation after a completed stapler fire using gray reloads on blood vessels, which can result in exposed vessels and bleeding that may require conversion to open surgery. As of February 23, the FDA said there have been four serious injuries and one death associated with the issue, and the agency is continuing to evaluate the situation.

Intuitive Surgical, Inc. (NASDAQ:ISRG) develops robotic-assisted surgical systems and related healthcare technologies.